Fenofibrate use while Breastfeeding
Drugs containing Fenofibrate: TriCor, Lofibra, Triglide, Antara, Lipofen, Lipidil Supra, Fenoglide, Lipidil Micro, Lipidil EZ
Medically reviewed by Drugs.com. Last updated on Oct 20, 2020.
Fenofibrate Levels and Effects while Breastfeeding
Summary of Use during Lactation
No relevant published information exists on the use of fenofibrate during breastfeeding. Because of a concern with disruption of infant lipid metabolism, fenofibrate is best avoided during breastfeeding. An alternate drug is preferred, especially while nursing a newborn or preterm infant. The manufacturer recommends that breastfeeding be avoided during fenofibrate therapy and for 5 days after the final dose.
Drug Levels
Maternal Levels. Relevant published information was not found as of the revision date.
Infant Levels. Relevant published information was not found as of the revision date.
Effects in Breastfed Infants
Relevant published information was not found as of the revision date.
Effects on Lactation and Breastmilk
Relevant published information was not found as of the revision date.
Substance Identification
Substance Name
Fenofibrate
CAS Registry Number
49562-28-9
Drug Class
-
Breast Feeding
-
Lactation
-
Anticholesteremic Agents
-
Antilipemic Agents
-
Fibric Acids
-
Disclaimer: Information presented in this database is not meant as a substitute for professional judgment. You should consult your healthcare provider for breastfeeding advice related to your particular situation. The U.S. government does not warrant or assume any liability or responsibility for the accuracy or completeness of the information on this Site.
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
